Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 441 (TSX: $AVCN.TO) (CSE: $IMCC.C) (OTC: $PSYC)
Delta, Kelowna, BC, July 15, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07151AVCN-IMCC-PSYC.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announced that its Rho Phyto™ product line of advanced medical cannabis products will be the subject of a Medical Cannabis Real-World Evidence study ("MC-RWE Study") led by Dr. Hance Clarke of the University Health Network ("UHN") in Toronto, Canada. The Rho Phyto products were developed in accordance with the recent Health Canada Cannabis 2.0 regulations that allow for more advanced, higher quality, medical cannabis product offerings. These products have been tested for prolonged stability, enhanced absorption, controlled delivery and other properties, in collaboration with Dr. Christine Allen's research group at the Leslie Dan Faculty of Pharmacy, University of Toronto.
The Rho Phyto medical cannabis product line is a full formulary that includes sublingual sprays, oil drops, capsules, and topicals of various cannabinoid ratios, namely THC and CBD.
By offering a variety of delivery systems, the medical community has the possibility to select the appropriate Rho Phyto product to suit a range of medical conditions such as pain relief, which may require either a fast onset of action or prolonged duration of effect over the course of treatment. The products are manufactured under good manufacturing practice ("GMP") in partnership with MediPharm Labs Inc. to ensure batch-to-batch consistency and high-quality products. The manufacture of the Rho Phyto products in accordance with GMP standard allows for data derived from this MC-RWE Study to provide early insights into Avicanna's ongoing and future directions of pharmaceutical development. Avicanna remains committed to patient safety and product consistency which is why all products subject to the MC-RWE Study are tested by Sigma Analytical and tracked by TruTrace Blockchain Technologies.
Dr. Justin Grant, Avicanna's Executive Vice President of Scientific Affairs commented, "After 3 years of collaborating with world-class Toronto-based researchers and clinicians including those at the University of Toronto and UHN, we are excited to offer the most consistent formulary of advanced medical cannabis products to prescribers and principal investigators, including Dr. Clarke, to further demonstrate the potential therapeutic efficacy of cannabinoids."
Avicanna's Rho Phyto products will be exclusively available to patients through the Medical
Cannabis by Shoppers online portal in addition to UHN clinicians through the MC-RWE Study by the end of July 2020. Additionally, Avicanna and Medical Cannabis by Shoppers are co-hosting a medical symposium in line with the launch of the Rho Phyto product line entitled, "MEDICAL CANNABIS 2.0: Advancements in Cannabinoid Research, Product Offerings and Patient Access". The symposium will be held on a virtual platform on July 21, 2020 and will include Dr Clarke's presentation "Real World Evidence and The Future of Medical Cannabis / Cannabinoid medicine for Pain Management" that will provide further insights on the MC-RWE Study. For registration and more information please visit (https://www.avicanna.com/symposium/).
The Health Depot Pharmacy and Lyte Medical announced their patient-centered online partnership; a venture that will help Canadians access medical care and prescriptions from the comfort and safety of their homes.
As Canadians adjust to a new reality and work to establish new daily routines; consistent access to healthcare and medications takes on even more importance. Virtual and direct-to-door prescription delivery are a necessity in meeting patients where they are.
According to the Canadian Radiotelevision and Telecommunications Commission, nationally, 86% of Canadian households have access to high speed internet. This online access presents health care practitioners and pharmacists with an opportunity to connect with patients remotely and remove some of the barriers to continuity of care including wait times, transportation, and scheduling.
In February 2020, The Canadian Medical Association, the Royal College of Physicians and Surgeons of Canada and the College of Family Physicians of Canada released a report on the future of virtual care in Canada. They emphasized the importance of prioritizing quality-based virtual care that truly respects the needs of Canadians.
"As a registered pharmacist since 2011, I have witnessed the evolution of health care in Canada. The Health Depot Pharmacy's partnership with Lyte Medical will allow Ontarians to see a physician and access their prescribed medications in a timely fashion", says Andy Donald, Founder & CEO of The Health Depot Pharmacy. "Our unique pharmacy services and approach allows necessary medications to be delivered promptly to those who rely on them, wherever and whenever they need them."
The Health Depot makes the pharmacy and healthcare shopping experience simple for all Ontarians. Their healthcare e-commerce store has thousands of health essentials available for online purchase and delivery, which can be shipped together with prescriptions for free.
Their Daily Dose Packs allow for an easy approach for patients who are taking multiple medications to have a simple, one daily packet approach, which is particularly helpful to seniors, caregivers, chronically ill, and individuals with special needs among others.
"Our forward thinking partnership with The Health Depot Pharmacy creates unprecedented access to a seamless virtual care experience. Canadians need medical care and medications in ways that accommodate their life circumstances", Ali Mohamed, CEO of Lyte Medical says. "Lyte Medical's virtual platform allows patients to speak to a doctor from the comfort of their own home and obtain their prescribed medications and health products online from The Health Depot Pharmacy, next day for free anywhere in Ontario with direct to door delivery."
Lyte Medical's patient friendly website makes connecting with a physician simple and easy. Lyte's comprehensive services include primary care, specialist referrals, mental health support, chronic pain treatment, and acute care. Patients will no longer have to take a day off from work, make childcare arrangements, or wait in line for their prescriptions, and for those living in rural areas, or vacationing at the cottage, The Health Depot and Lyte Medical will bring healthcare to Canadians at home, wherever that may be.
IM Cannabis Corp. (CSE: IMCC), a multi-country operator ("MCO") in the medical cannabis sector with operations in Israel and across Europe, announced that its German subsidiary, Adjupharm GmbH, has received a definitive purchase commitment of medical cannabis over the next twelve months from Zur Rose Pharma GmbH, an established distributor in Germany. This is the Company's fourth definitive purchase commitment with a distributor in Germany and advances IMC's strategy of creating a network of distribution partnerships to maximize penetration of IMC-branded products.
"We have now signed our fourth sales agreement with a binding purchase commitment. More importantly, we have added Zur Rose Pharma GmbH as a key partner, a well-established and reputable pharmaceutical service provider and wholesaler that bolsters our ability to provide quality medical cannabis products across the large and dynamic German market. As we continue to add trusted partners to our MCO network, we firmly believe that we have created a strong foundation to become the preeminent brand in international medical cannabis," said Oren Shuster, CEO of IMC.
"The momentum IMC has established within the German market is indicative of strong demand and favourable industry fundamentals for medical cannabis. With the launch of the IMC brand in Germany in Q3 2020, we have been deploying our sales teams to further physician education across the country and build our brand's reputation as a reliable provider of top quality medical cannabis to patients, pharmacists and physicians," added Richard Balla, CEO of Adjupharm.
Through its EU-GMP certified subsidiary, Adjupharm, the Company has entered into a three-year sales agreement with the medical cannabis distributor Zur Rose Pharma GmbH in Germany. This distributor has entered into a purchase commitment under its sales agreement.
IMC has also previously announced that Focus Medical Herbs Ltd. has signed six binding sales agreements for the distribution of IMC-branded medical cannabis products in Israel. Total consolidated revenue from all binding sales agreements in Israel is expected to be $193.5 million with an expected gross margin of 50%. A total of 33,075kg of medical cannabis will be delivered in Israel between Q2 2020 and 2023, and 3,000kg of medical cannabis under the sales agreements is expected to reach pharmacies in 2020.
Global Trac Solutions, Inc. (OTC: PSYC) announced the 2nd monthly release and distribution of the July edition of its Microdose Monthly newsletter, which features three articles that provide an overview of Kevin O’Leary’s investment participation with MindMed, a review of Gwyneth Paltrow’s Goop Lab on Netflix, and an exclusive one-on-one interview with Chi Psilocybin, a prominent voice for the psychedelic reform movement and owner of Truffles Therapy in Amsterdam.
The interview with Chi, amply titled “A Servant of the Mushroom Kingdom,” is an in-depth look at a personal journey and discovery of the benefits associated with a life-long affinity for psychedelics and finding life’s passion and purpose. On a trip to Thailand, Chi met his future wife and co-founder of their company, Truffles Therapy, a psilocybin retreat that has become his life’s work and has hosted many hundreds of “journeyers” from all over the world. Chi believes that everyone should have the opportunity to experience the magic of mushrooms.
David Flores, Global CEO, said, “I would like to personally thank Chi for taking the time to share his unique and fascinating story with us and for the voice he lends to the psychedelic reform movement taking place across the globe. Chi is playing a vital role in the industry’s continued emergence into society’s mainstream, which is showing great promise through clinical studies for treating debilitating mental health conditions, in addition to improving quality of life for millions across the globe. I believe that our subscribers are really going to enjoy this month’s latest newsletter written by Mr. Kent Sligh, Global’s Creative Content Director. Furthermore, I look forward to developing our network of industry leaders and advocates and exploring opportunities throughout this process to establish some of the strategic partnerships that will in time contribute to our emergence as an industry leader for news and information.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
No comments:
Post a Comment